Bleomycin Sulfate

製品コードS1214 別名:NSC125066

Bleomycin Sulfate化学構造

分子量(MW):1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ 価格(税別)  
JPY 28220.00
JPY 111220.00

質量管理及び製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3lVndpOOLCk{GwNFAh|ryv M{nWRlI1KGkEoB?= NVLvNm82cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MVGyOlA5QDdzMR?=
POLK WT MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P1W2lEPTB;MUGuO-KBkcLz4pEJNU44yqEQvF2= MoPENlYxOzF2MEC=
POLK KO M{DreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSzTWM2OD12LkCz5qCKyrIkgJmxMlkzyqEQvF2= NV;xdotROjZyM{G0NFA>
POLK CD MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PjfmlEPTB;NT61PgKBkcLz4pEJNU4xOMLizszN Mki2NlYxOzF2MEC=
RLE/Abca3 M4K4b2Z2dmO2aX;uJGF{e2G7 MnXWNE41yqEQvF2= NUPkR4NTOTR2wrDo NFXWNINqdmS3Y3XzJIEhdW:{cHjvcI9ocWOjbDDjbIFv\2ViZoLvcUBmeGm2aHXsbYFtNWyra3WgcY9zeGixbH;nfUB1dyCjIIfp[IUtKHOycnXh[E1wfXRibX;ydIhwdG:pedMg NUfKbWI2OjV5NkC1N|g>
PMCs NFvDbHVHfW6ldHnvckBCe3OjeR?= MmLwNE4y6oDVMtMg{txoN22u MlXaNlTDqGh? Mln5Z4F2e2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKHC{b4TlbY4hdGW4ZXygc4Yh[2:ubHHn[Y4uUcLi NI\2TGgzPTV7NU[0Ni=>
PMCs NV75PYYxTnWwY4Tpc44hSXO|YYm= MYGwMlLDqM7:Zz;tcC=> MlrKNlTjiJN5MtMgbC=> MlnibY5lfWOnczDpcoNz\WG|ZYOgbY4hfmmvZX70bY4h[W6mIN8xMXNOSSCycn;0[Ylv M3eydFI2PTl3NkSy
PMCs MmPHSpVv[3Srb36gRZN{[Xl? NXuzeXhjOC5{wrFOwIcwdWx? MXS3NkBp MVvpcoR2[2W|IHTlZ5Jm[XOnczDpckBkgXSxa3XyZZRqdi16IHHu[EBGNWOjZHjldolvKHC{b4TlbY4> NV62[497OjV3OUW2OFI>
PMCs NGfPUppHfW6ldHnvckBCe3OjeR?= NVP2OYFwOC5{wrFOwIcwdWx? NILvNXAyOi9{ND:0PEBp MojDbY5kemWjc3XzJINmdGxibXnndoF1cW:w NVTHVXlXOjV3OUW2OFI>
IMR-32 NV7pUHhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnkcIE4NjYkiKKxNlAhyrWpL33s M1vkXlEz6ojUNEigbC=> M{PRUGlEPTB;NkCgxtVoN22uIHH0JJRp\SCnbnSgc4YhOjRiaILzJI9nKGmwY4XiZZRqd25? M3joU|I2PTN4M{S1
HT1080 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vRNFEh|ryP M3LmSFI1KGkEoB?= MkT0cIVi\HNidH:gZUBIOi:PIHTlcIF6 MXmyOVUyQDl4MR?=
HT1080 M4HDe2Z2dmO2aX;uJGF{e2G7 Mk\TNUDPxE1? M1rCeFI1KGkEoB?= NYjucnVncW6mdXPld{BiKHCxdHXueEBodG:kYXygSG5CKGSjbXHn[UBz\XOyb37z[S=> NV3QeopTOjV3MUi5OlE>
HDFn MoT6R5l1d3SxeHnjbZR6KEG|c3H5 MmPkO|IhcA>? NWLYVItLUUN3ME25MlMyLcLi MWOyOVI4Pjd7Mh?=
THP-1 NFTkZXVEgXSxdH;4bYNqfHliQYPzZZk> MYS3NkBp NYjXSYJXUUN3ME20Mlc4LQ>? NXHFTmdXOjV{N{[3PVI>
HT-29 MlTWR5l1d3SxeHnjbZR6KEG|c3H5 MYG3NkBp NXHjR2lMUUN3ME2xNU41QSV? Mk\RNlUzPzZ5OUK=
HCT116  NVzvTpo1S3m2b4TvfIlkcXS7IFHzd4F6 MWm3NkBp MkDQTWM2OD1zMT6zOEU> NGTZbFgzPTJ5Nke5Ni=>
A431 NWDqOnM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7BOVAuOjByIFnV Mk[1OFjjiImq MVfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M{jXTVI2OTBzMkm5
T24 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu1NE0zODBiSWW= NXS5Um9sPDkkgJno MonobY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MmfkNlUyODF{OUm=
AY-27  NWfDWHdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm2XFA2OC1{MECgTXU> NFfsXnM1QOLCiXi= MUDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NV;INJJ4OjVzMEGyPVk>
A549 M{TSRmZ2dmO2aX;uJGF{e2G7 Mn7QNUDDvWdxbV|CpC=> M{HsWFAuPDhiaB?= NELITW1qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4bDqE:STtMgcXJPSQ>? NIn6eHkzPDl4M{[zOS=>
MLE12 M2fuOmZ2dmO2aX;uJGF{e2G7 M2XMSVEhyrWpL33MxsA> NIPabYMxNTR6IHi= MX7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> MnrvNlQ6PjN4M{W=
Jurkat M1XwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPONlDjiIoQvH2= Mn:3NlTjiImqwrC= MmG0ZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> M3TDXFI1QTF4OEmz
HeLa  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHRcoRKSzVyPUGwMlLDqM7:TR?= M33mO|I1PzN{M{m3
C18-4 NXjhUGZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf1fJNyOC1zMECg{txO M2nNWolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NGnmclkzPDV5MUm4Ni=>
BMG-1  M2PNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLWOFAwQDEEoN88[{9u M4XCNVPDqGh? NFfaeI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MUCyN|kxPjd{Nh?=
A459 NX\OOJd5SXCxcITvd4l{KEG|c3H5 MmjHNVAhdVV? MX60PEBp NFjHbm1qdmS3Y3XzJIFxd3C2b4Ppdy=> MmLZNlM6ODJ5Nk[=
MOCK NYDL[ZQxSXCxcITvd4l{KEG|c3H5 MmfYNVAhdVV? NVLWS2lFPDhiaB?= NIT2RplqdmS3Y3XzJIFxd3C2b4Ppdy=> MXyyN|kxOjd4Nh?=
MMP1 NFP0S5dCeG:ydH;zbZMhSXO|YYm= NWnMbYpqOTBibWW= NUP0VVlmPDhiaB?= Mmq2bY5lfWOnczDhdI9xfG:|aYO= NIX0NogzOzlyMke2Oi=>
A549 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[0S|kzODBizszN MmXHNlQhcMLi NEPQdFRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NHPMR|kzOzhyNUe5Ny=>
HCT-116 NFjhdGZCeG:ydH;zbZMhSXO|YYm= MVizM|cvPS9zNTFOwIcwdWx? NEDE[mk1QCCq MnvUdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NX7S[WI1OjN5MEi2Olg>
HeLa MXzBdI9xfG:|aYOgRZN{[Xl? NVu5WpJTOy95LkWvNVUh|rypL33s M4\kSlQ5KGh? MXjy[YR2[2W|IITo[UBt\X[nbDDv[kBDVEhiYYSgbIlocCClb37j[Y51emG2aX;u NHXXVoYzOzdyOE[2PC=>
HCT116 NGH0TFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzXR5ExNTFyMDFOwIcwdWx? MVm0PEBp Mmq5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M13TelI{PTF6MkCx
NCM460 NY\UeJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOwMVExOCEQvHevcYw> NIezboM1QCCq NI\uSJZqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NVuzd3B3OjN3MUiyNFE>
NT2  MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWyOEBpyqB? MnH2UGQ2OD12MEFihKnDvWdxbXy= NX3MS|l7OjN|OE[0NlA>
NT2  NV3tO29lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCyOFghcA>? MlnnUGQ2OD1zMECgxtVoN22u NXvGflNKOjN|OE[0NlA>
NT2  M{\UUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITYc2Q4OiCq MYnMSFUxRTJy4pEJxtVoN22u NWjLdokxOjN|OE[0NlA>
NT2  NFy0WVdCeG:ydH;zbZMhSXO|YYm= M3;oVlQxOOLCidM1[{9udA>? Mn3FNlQhcMLi MorabY5lfWOnczDzbYdvcW[rY3HueEBqdmO{ZXHz[ZMhcW5iY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh MnLjNlM{QDZ2MkC=
NTera-2 NI\3SZpHfW6ldHnvckBCe3OjeR?= M4LJelEzOCEQvHevcYw> MVK3NkBp MmXMd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= NX;Z[HZ1OjJ6MkWzOVU>
NCCIT NIDRXmRHfW6ldHnvckBCe3OjeR?= NYC4U4hjOTJyIN88[{9udA>? M3n5U|czKGh? M{TmdpNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz NXm1UnBDOjJ6MkWzOVU>
NTera-2 MUHGeY5kfGmxbjDBd5NigQ>? NXXXNW5uOTJyIN88[{9udA>? M3rDRlczKGh? NV7kUlBme2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ NIHqdlAzOjh{NUO1OS=>
NCCIT NEKybWtHfW6ldHnvckBCe3OjeR?= NU\tTWNbOTJyIN88[{9udA>? M4DySVczKGh? M1XXS5Nq\26rZnnjZY51dHliaX7jdoVie2W|IGTCRXJUKGyndnXsdy=> MmHmNlI5OjV|NUW=
NCCIT NUWyfnA{TnWwY4Tpc44hSXO|YYm= NIW2fnEyOjBizsznM41t M2\PflczKGh? MnXud4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiR2PIJIxmfmWucx?= Mny1NlI5OjV|NUW=
NTera-2 MYrGeY5kfGmxbjDBd5NigQ>? MnLRNVIxKM7:Zz;tcC=> NGDzc4o4OiCq NWfHcmoxe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgVJJwfGWrbjDjZZJjd267bDDs[ZZmdHN? M{njOVIzQDJ3M{W1
NCCIT NUnYUpZvTnWwY4Tpc44hSXO|YYm= MWixNlAh|rypL33s NHT3d5I4OiCq Mn\Sd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MViyNlgzPTN3NR?=
NTera-2 NWjvfWh[TnWwY4Tpc44hSXO|YYm= NXP0b5U5OTJyIN88[{9udA>? NEXQcGM4OiCq M2LCUZNq\26rZnnjZY51dHliaX7jdoVie2W|IFzQU{Bt\X[nbIO= MWOyNlgzPTN3NR?=
NCCIT M4PNXmZ2dmO2aX;uJGF{e2G7 Mn7VNVIxKM7:Zz;tcC=> NV21SVdCPzJiaB?= MWPzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCOUF:gcIV3\Wy| NH\tNlkzOjh{NUO1OS=>
MDA-MB-468 M3zuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[w5qCUOjBywrFOwIcwdUx? M2\NeVI1KGh? MWHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MV2yNlgyQTF7Nh?=
231-H2N MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu1R|Ax6oDVMkCwxsDPxGdxbVy= MorVNlQhcA>? MV\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MWqyNlgyQTF7Nh?=
A549  MY\GeY5kfGmxbjDBd5NigQ>? M2HLclIxOC92MECg{txO MkTndoV{fWy2czDpckBiKGSxc3WtdoV{eG:wc3n2[UBqdmO{ZXHz[UBqdiCUT2O= MWKyNlc4OzZ7Nx?=
A549  NIrGVFRHfW6ldHnvckBCe3OjeR?= NFjDWWsxNTRyMDFOwG0> M{jySVIuPDhiaB?= NIPWRmRk[XW|ZYOgcY9z\SCvdFTORUB1cGGwIH7EUmEh\GGvYXfl M3n0TlIzPzd|Nkm3
A549  MomySpVv[3Srb36gRZN{[Xl? MmTXNVAxKM7:TdMg NXzxVHBZOOLCk{S4JIg> M3TCdINifXOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MmOwNlI4PzN4OUe=
A549  NGHuPGZHfW6ldHnvckBCe3OjeR?= NFO4d3UyODBizszNxsA> NXPQclI4OOLCk{S4JIg> NFrZTnlk[XW|ZYOgVGtFOSClbHXheoFo\Q>? MYiyNlc4OzZ7Nx?=
A549  MWjGeY5kfGmxbjDBd5NigQ>? MXexNFAh|ryPwrC= NYDNS2hTOOLCk{S4JIg> NIrKPGtk[XW|ZYOgcYl1d2Oqb37kdolidCCub3PhcIl7[XSrb36gc4YhSmG6 NUD4R3FCOjJ5N{O2PVc>
A549  M2T3TWZ2dmO2aX;uJGF{e2G7 MkTWNVAxKM7:TdMg MVGw5qCUPDhiaB?= NWLnW5NT\GWlcnXhd4V{KE2PUDDhcoQhSVSSIHzleoVtew>? NHvjUIczOjd5M{[5Oy=>
MCF-7/Her-18  NWLBdXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\TNE41Oi1zN{CwJO69\y:vTB?= MWGyOEBp NH;hc5lqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M1myT|IzPjJzNEC0
MCF-7 M2HpTHBFXC:SQ1mgWJJm[XSvZX70 M2Lo[FAvOjVizsznM41tNg>? NWruVYpxOS12IHi= NFezSHR{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 NV:1Z3RIOjJ3OUGyPFQ>
MDA-MB-231 NGOxWYpRTFRxUFPJJHRz\WG2bXXueC=> MofFNE4zPSEQvHevcYwv MV[xMVQhcA>? M4j0d5Npd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> Mo\SNlI2QTF{OES=
MDA-MB-235  M3rwVXBFXC:SQ1mgWJJm[XSvZX70 NE\hSlYxNjJ3IN88[{9udC5? MV6xMVQhcA>? MXPzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 MkDlNlI2QTF{OES=
MCF-7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HrZlAuOiEQvHevcYwv NWPGOJRTOjRxNEigbC=> NFztNINGSzVyPUGuNkDPxGdxbVy= M{\adFIzPTlzMki0
NCCIT  MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfqXlJJOjEkgKOxOFDDqM7:Zz;tcC=> MX[3NkBp NXzYcIVDVER3ME2xNlDDqM7:Zz;tcOKh MWeyNlU3OjF4MB?=
NCCIT  MlH3SpVv[3Srb36gRZN{[Xl? MoLVO|IhcA>? MWfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTNiYXP0bZZqfHoEoB?= MWqyNlU3OjF4MB?=
NCCIT  MnTsSpVv[3Srb36gRZN{[Xl? Mnz1O|IhcA>? MkW4d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S16IHHjeIl3cXS7wrC= MVKyNlU3OjF4MB?=
NCCIT  M2npcWZ2dmO2aX;uJGF{e2G7 NVTpWXd3PzJiaB?= NHf1SpJ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUmgZYN1cX[rdIpCpC=> MUSyNlU3OjF4MB?=
NCCIT  M3\LVWZ2dmO2aX;uJGF{e2G7 MnvpO|IhcA>? MUDzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NGrURY8zOjV4MkG2NC=>
NCCIT  M{i5fmZ2dmO2aX;uJGF{e2G7 MoK0O|IhcA>? MWDzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgRoNtNTJiY3;ueIVvfA>? NHfR[GozOjV4MkG2NC=>
NCCIT  NXr0fpdVTnWwY4Tpc44hSXO|YYm= MUe3NkBp MoTpd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGN6fC2lIHzleoVt NYrRT5QzOjJ3NkKxOlA>
HeLa NU\tTHVPTnWwY4Tpc44hSXO|YYm= NXzmSZBiOzBxN{Cg{txoN22u MYSyOOKhcA>? M33YRYlv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 Mlv2NlI1QDd7M{e=
MCF-7  NI\o[2FHfW6ldHnvckBCe3OjeR?= NIjpXmM{OC95MDFOwIcwdWx? NFTSOGUzPMLiaB?= NHPwPW5qdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? NHHlUFkzOjR6N{mzOy=>
HeLa MmrZR5l1d3SxeHnjbZR6KEG|c3H5 MWWzNE84OCEQvHevcYw> NE\Ze|EzPMLiaB?= MUDpcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? NH7sdmEzOjR6N{mzOy=>
MCF-7  MWrDfZRwfG:6aXPpeJkhSXO|YYm= M1TIPVMxNzdyIN88[{9udA>? MV6yOOKhcA>? MmrtbY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv NXSzOmFXOjJ2OEe5N|c>
NT2 NFPBeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHo[|U1OTByLU[wNOKh|rypL33s Mnv3NlQhcA>? NHnLSpFKSzVyPUSwNEDDvWdxbXy= MVGyNlQ3QTl3Mh?=
NT2 NHX6T5dHfW6ldHnvckBCe3OjeR?= NYjifGJGPDBywrFOwIcwdWx? MV:yOEBp NEjFNYR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? NHXGfFIzOjR4OUm1Ni=>
NT2 MofTSpVv[3Srb36gRZN{[Xl? NGWxbWI1ODEEoN88[{9udA>? NF;HcI0zPCCq Mn3hd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu NHG4S4czOjR4OUm1Ni=>
NT2 M1LWXWZ2dmO2aX;uJGF{e2G7 NEDSZ2M1ODEEoN88[{9udA>? M3G1R|I1KGh? M4nlc5Nq\26rZnnjZY51dHliZHXjdoVie2W|IFLjcE0zKGyndnXs M3LndVIzPDZ7OUWy
CHO MUPGeY5kfGmxbjDBd5NigQ>? NHjsW|EzNjYEoN88[{9udA>? MnjGNVghcC94IHS= Mnr5bY5lfWOnc9MgdIVze2m|dHXuZ4Uhd2ZiY3jyc41we2:vZTDkZY1i\2V? NF:yZnYzOjJ|MEG5OS=>
Jurkat NXW3bHZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHqd48xNTFyMNMg{txoN22u NI\BPXkzPCCq MXThdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> M{m5TVIzOjJ|M{Oy
Jurkat MWXGeY5kfGmxbjDBd5NigQ>? M2WxVFMxyqEQvHevcYw> NY\6Nmt6OjRiaB?= M{XMeolv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiY4njcIlveyCGMzygRUBidmRiQkG= NXPlTW96OjJ{MkOzN|I>
Jurkat MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\1NE0yODEEoN88[{9udA>? M4PnOFI1KGh? NXyyXZl[cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigZY4hUUN3MDD2ZYx2\SCxZjCxNFDPxGdxbVy= MXuyNlIzOzN|Mh?=
Jurkat M3jRZWZ2dmO2aX;uJGF{e2G7 Mo\vN|DDqM7:Zz;tcC=> M3\ZblI1KGh? MVnpcoNz\WG|ZYOgeIhmKGWoZnXjeEBw\iCyeXPubYRqd26nIH;uJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNib3[gbIl{fG:wZTDINmEvYA>? MUGyNlIzOzN|Mh?=
U2OS EGFPnls M{LvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD6T5hsOC1{wrFOwIcwdWx? MoKxNlQhcA>? NGfYNYJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NVS0NGt7OjF6MUGwNFc>
U2OS KuEnls Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6wMVLDqM7:Zz;tcC=> NUPTUXhJOjRiaB?= NVzNOHk2cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M4HiVVIyQDFzMEC3
MCF-7 NWLKRld1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LoZ|AuPDByIN88US=> NFPEfm84OiCq M4HLbGxEPTB;MUWxMljDqM7:TR?= MnTaNlE4ODN{OUG=
MCF-7/Adr  MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPrPWNoOC12MECg{txO NFLodow4OiCq M{LXU2xEPTB;NUiuOeKh|ryPwrC= MofwNlE4ODN{OUG=
WI-38 NI[zWW9HfW6ldHnvckBCe3OjeR?= MoTVNE81OC96MPMAje69\y:vbNMg NU\ubXFoOyCq NX\zUWF2cW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? M1jIW|IyPTl7NkGy
hBMSC MXPGeY5kfGmxbjDBd5NigQ>? NYq0S4J2OC92MD:4NQKBkc7:Zz;tcOKh MXmzJIg> NYTBXZo{cW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? M4TlOVIyPTl7NkGy
NCI-H23 MXnGeY5kfGmxbjDBd5NigQ>? NXzuSW9pOC92MD:4NQKBkc7:Zz;tcOKh NUTvOVRDOyCq M{jHdYlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> MVOyNVU6QTZzMh?=
A-549 NEPqNVFHfW6ldHnvckBCe3OjeR?= MmDrNE81OC96MPMAje69\y:vbNMg MXOzJIg> NHLvNVVqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NETtRpIzOTV7OU[xNi=>
PBL  NIrxcIVHfW6ldHnvckBCe3OjeR?= MUGwM|QxNzhy4pEJ{txoN22uwrC= NEDNZ4k{KGh? MkTsbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NUHrV243OjF3OUm2NVI>
pol β −/− NEPG[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUiwMlI2NTJyMNMg{txoN22u MViyOOKhcA>? NY\SUIpR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li NUL6VHdEOjF{NUG5OFQ>
pol β +/+ NITsdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7qO5gxNjJ3LUKwNOKh|rypL33s M1\DcVI1yqCq MXrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3n0bEBqdmO{ZXHzbY5oKGOxbnPlcpRz[XSrb37zxsA> NGLQOJMzOTJ3MUm0OC=>
pol β −/− NGH4U5lHfW6ldHnvckBCe3OjeR?= MnziNE0zNjVizsznM41t MoS2NkBp M1u2[4NifXOnczDEUmEh\GGvYXfl NXryfXQ6OjF{NUG5OFQ>
pol β +/+ NE[0cFJHfW6ldHnvckBCe3OjeR?= MnnKNE0zNjVizsznM41t NF;pc4QzKGh? MmnZZ4F2e2W|IFTORUBl[W2jZ3W= MVKyNVI2OTl2NB?=
pol β −/− MYPGeY5kfGmxbjDBd5NigQ>? NYL4dXlROC13IN88[{9udA>? NH;Md|Q1QCCq MW\jZZV{\XNibXnjdo9vfWOuZYXzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NGTlVnczOTJ3MUm0OC=>
pol β +/+ NUf1c|RFTnWwY4Tpc44hSXO|YYm= Mnz0NE02KM7:Zz;tcC=> NXH1NYRUPDhiaB?= NW\rOVFr[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M{jVOFIyOjVzOUS0
TK6  MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6yOU0yPTBizsznM41t MlvLPVYhcA>? NFjFWWNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MXqyNVA5OTR6Nx?=
TK6  sLUC+Apn1 M1O0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:5W4YzPS1zNUCg{txoN22u MmfrPVYhcA>? MljWbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NUfXR5g1OjFyOEG0PFc>
TK6 sAPE1+Apn1 M{Ppfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWyOU0yPTBizsznM41t MUW5OkBp NGrxZmx{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= M2C3RVIyODhzNEi3
HCT116 NYX3PGlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjYb2M{OjVvMUWwJO69\y:vbB?= MUW5OkBp MWjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M33TUVIyODhzNEi3
HCT116 sLUC+Apn1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u2dVI2NTF3MDFOwIcwdWx? MVu5OkBp M4HNcolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M3K0bVIyODhzNEi3
HCT116 sAPE1+Apn1 NEDPeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor4NlUuOTVyIN88[{9udA>? M37qXFk3KGh? NEfxe3l{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= NH\OTXkzOTB6MUS4Oy=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

お薦めの試験操作(参考用のみ)

細胞試験:

[4]

+ 展開
  • 細胞株: ADIPO-P2 cells
  • 濃度: 2.5 μg/mL
  • 反応時間: 30 minutes
  • 実験の流れ:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: CD-1 mice
  • 製剤: Saline
  • 投薬量: 5 mg/kg, 2 ml/kg
  • 投与方法: Administered via i.t.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (66.11 mM) warming
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 1512.62
化学式

C55H85N17O25S4

CAS No. 9041-93-4
保管
in solvent
別名 NSC125066

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Bleomycin Sulfateを買う | Bleomycin Sulfate ic50 | Bleomycin Sulfate供給者 | Bleomycin Sulfateを購入する | Bleomycin Sulfate費用 | Bleomycin Sulfate生産者 | オーダーBleomycin Sulfate | Bleomycin Sulfate化学構造 | Bleomycin Sulfate分子量 | Bleomycin Sulfate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID